These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12702541)

  • 1. Bisphosphonates: new antiangiogenic molecules in cancer treatment?
    Vincenzi B; Santini D; Rocci L; Tonini G
    Ann Oncol; 2003 May; 14(5):806-7. PubMed ID: 12702541
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates in cancer therapy.
    Stresing V; Daubiné F; Benzaid I; Mönkkönen H; Clézardin P
    Cancer Lett; 2007 Nov; 257(1):16-35. PubMed ID: 17697748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
    Santini D; Schiavon G; Angeletti S; Vincenzi B; Gasparro S; Grilli C; La Cesa A; Virzí V; Leoni V; Budillon A; Addeo SR; Caraglia M; Dicuonzo G; Tonini G
    Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):383-96. PubMed ID: 18221048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic effects of zoledronate on cancer neovasculature.
    Metcalf S; Pandha HS; Morgan R
    Future Oncol; 2011 Nov; 7(11):1325-33. PubMed ID: 22044205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonates in oncology].
    Soltau J; Medinger M; Unger C; Drevs J
    Med Monatsschr Pharm; 2003 Dec; 26(12):411-7. PubMed ID: 14699777
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model.
    Soltau J; Zirrgiebel U; Esser N; Schächtele C; Totzke F; Unger C; Merfort I; Drevs J
    Anticancer Res; 2008; 28(2A):933-41. PubMed ID: 18507039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?
    Tanvetyanon T
    Med Hypotheses; 2004; 63(4):764-5. PubMed ID: 15325030
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro and in vivo antitumor effects of bisphosphonates.
    Clézardin P; Fournier P; Boissier S; Peyruchaud O
    Curr Med Chem; 2003 Jan; 10(2):173-80. PubMed ID: 12570716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.
    Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV
    Oncology; 2009; 76(3):209-11. PubMed ID: 19212145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
    Ayllon J; Launay-Vacher V; Medioni J; Cros C; Spano JP; Oudard S
    Ann Oncol; 2009 Mar; 20(3):600-1. PubMed ID: 19188135
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiogenic tumor markers, antiangiogenic agents and radiation therapy.
    Chan LW; Camphausen K
    Expert Rev Anticancer Ther; 2003 Jun; 3(3):357-66. PubMed ID: 12820778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic agents.
    Wilkes G
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl Nurse Ed):48. PubMed ID: 17474365
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance to antiangiogenic therapies.
    Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA
    Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of bisphosphonates in prostate cancer.
    Oades GM; Coxon J; Colston KW
    Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfoglycolipids as candidate antiangiogenic radiosensitizers.
    Miura M; Sakimoto I; Ohta K; Sugawara F; Sakaguchi K
    Anticancer Drugs; 2007 Jan; 18(1):1-5. PubMed ID: 17159496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of novel antiangiogenic therapies.
    Scappaticci FA
    Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimetastatic drugs in prostate cancer.
    Chay CH; Cooper CC; Hellerstedt BA; Pienta KJ
    Clin Prostate Cancer; 2002 Jun; 1(1):14-9. PubMed ID: 15046708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide, an antiangiogenic agent with clinical activity in cancer.
    Ng SS; Brown M; Figg WD
    Biomed Pharmacother; 2002 Jun; 56(4):194-9. PubMed ID: 12109812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring responses to antiangiogenic agents using noninvasive imaging tests.
    Libutti SK; Choyke P; Carrasquillo JA; Bacharach S; Neumann RD
    Cancer J Sci Am; 1999; 5(5):252-6. PubMed ID: 10526663
    [No Abstract]   [Full Text] [Related]  

  • 20. Do not say ever never more: the ins and outs of antiangiogenic therapies.
    Quesada AR; Medina MÁ; Muñoz-Chápuli R; Ponce ÁL
    Curr Pharm Des; 2010; 16(35):3932-57. PubMed ID: 21158731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.